AbbVie Down Since Q4 Earnings Report: How to Play the Stock

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Phase III data with Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus expected in 2026

  80% confidence

• Aesthetics category growth expected to remain challenged in 2026

  80% confidence

• Oncology pipeline is robust with several study readouts and initiations expected this year

  80% confidence

• No significant LOE (loss of exclusivity) events for the rest of this decade

  80% confidence

• Expects high single-digit revenue growth through 2029

  80% confidence

• Expects low single-digit pricing headwind for both Skyrizi and Rinvoq in 2026 and over the next few years

  80% confidence

• Vyalev expected to achieve blockbuster status in 2026, with sales expected to ramp up substantially in the United States

  80% confidence

• Combined Skyrizi and Rinvoq sales expected to exceed $31 billion in 2026

  80% confidence

• Global aesthetics sales expected to be $5 billion in 2026, flat from 2025 levels

  80% confidence

• Total revenues expected to rise approximately 9.5% in 2026

  80% confidence

• Next wave of potential approvals in Rinvoq could add roughly $2 billion to peak-year sales for the product

  80% confidence

• AbbVie stock is a Zacks Rank #3 (Hold)

  80% confidence

• Rinvoq could be approved for two indications — vitiligo and alopecia areata in 2026

  80% confidence

Data points we hold from this source